

IN VITRO THYMIDINE PHOSPHORYLASE INHIBITORY AND ANTIGLYCATION POTENTIALS OF *ANABASIS ARTICULATA* HPLC PURIFIED FRACTIONS

JAN, M.¹ – ZAHOR, M.^{1*} – KHAN, M.² – HAYAT, M. F.³ – ESA, M.⁴ – ULLAH, R.⁵ – ALOTAIBI, A.⁶

¹Department of Biochemistry, University of Malakand, Chakdara, Dir Lower, KPK 18800, Pakistan
(e-mail: jmarwa084@gmail.com)

²College of Chemistry, Fuzhou University, 350116 Fuzhou, China
(e-mail: majidk166@yahoo.com)

³North West Institute of Health Sciences, Hayatabad Peshawar, KPK, Pakistan
(e-mail: fhayat004@gmail.com)

⁴Drug Delivery System Excellence Center, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
(e-mail: esakhan5595@gmail.com)

⁵Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
(e-mail: rullah@ksu.edu.sa)

⁶Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia
(e-mail: amaalotaibi@pnu.edu.sa)

*Corresponding author
e-mail: mohammadzahoorus@yahoo.com

(Received 7th May 2025; accepted 30th Jun 2025)

Abstract. *Anabasis articulata*, a medicinal plant renowned for its abundance of bioactive constituents, has been studied for its antioxidant, anticancer, and antidiabetic potentials. Our previous research highlighted its significant antioxidant, anti-inflammatory, and antidiabetic activities. Herein, we extend on thymidine phosphorylase (TP) inhibitory and antiglycation potential of HPLC-purified fractions of *A. articulata* stem and leaves methanolic extract. TP is a key enzyme in angiogenesis and cancer progression, whereas protein glycation is associated with metabolic illnesses, including diabetes and neurological disorders. The methanolic extract of *A. articulata* was subjected to silica gel chromatography, resulting in four pure fractions (A-1, D-1, B-1, C-1). Results showed that A-1 and B-1 exhibited highest TP inhibition (87.1 and 90.4%) with an IC₅₀ of 1.9 ± 0.9 and 3.1 ± 0.2 mg/mL, respectively. Furthermore, the antiglycation test showed significant inhibitory effects, with fraction C-1 exhibiting the strongest antiglycation activity (89.7%, IC₅₀ = 0.11 ± 0.002 mg/mL), followed by A-1 (87.3%, IC₅₀ = 2.68 ± 0.098 mg/mL). The findings indicated that *A. articulata* exhibited considerable therapeutic effects in combating cancer-related angiogenesis and glycation-associated metabolic diseases such as diabetes.

Keywords: angiogenesis, bioactive compounds, protein glycation, in vitro activities, natural inhibitors, medicinal plants

Introduction

Plants have long been utilized for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic disorders, and other diseases, due to their

rich reservoir of bioactive compounds (Teodoro, 2019). Specifically, they produce diverse secondary metabolites that exhibit significant anticancer, neuroprotective, and metabolic disorder-modulating properties (Seca and Pinto, 2018). Some of these metabolites exert anticancer effects by inhibiting cancer cell proliferation, preventing metastasis, and suppressing angiogenesis, etc. Angiogenesis, a key factor in tumor growth, has been a major therapeutic target for the past five decades (Majnooni et al., 2023). Thymidine phosphorylase (TP) is one such factor that promotes blood vessel growth and is recognized as a validated target for antiangiogenic drug development (Alam et al., 2024). In metabolic disorders like diabetes, it acts as an inhibitor of α -amylase, α -glucosidase, and advanced glycation end-product (AGE) formation, which is also implicated in Alzheimer's disease, among other mechanisms (Lan et al., 2024).

Inhibiting the process of angiogenesis is considered a promising strategy to combat cancer progression, while the inhibition of glycation is crucial in managing in metabolic disorders such as diabetes, and age-related diseases like Alzheimer's disease. TP facilitates tumor angiogenesis and is an important contributor to cancer progression, thus serving as an optimal target for the development of anti-angiogenic drugs and preclinical experiments (Bronckaers et al., 2009). The overexpression of TP has been linked to cancer aggressiveness and survival. Various solid tumors, such as breast, colorectal, bladder, and esophageal cancers, are associated with elevated levels of TP (Javaid et al., 2019). Moreover, other conditions, like rheumatoid arthritis, psoriasis, and inflammation, also have elevated TP activity levels (Hammiche and Maiza, 2006). Multiple TP inhibitors have demonstrated significant in vitro efficacy; however, only one, tipiracil, used in combination with the cytotoxic drug trifluridine, has received US FDA approval for the treatment of gastrointestinal malignancies (Peeters et al., 2018). The administration of this combination medicine (Lonsruf®) is hindered by numerous adverse effects, including neutropenia, anemia, and myelosuppression, among others (Lee and Chu, 2017).

Given the importance of TP in cancer and of antiglycation in diabetes mellitus, Alzheimer's disease, and the progression of atherosclerosis, plant extracts and phytochemical fractions (pure compounds) isolated from plants have been reported to exhibit antiglycation activity. Saffron (*Crocus sativus* L.) extract, with crocin as the key bioactive carotenoid, demonstrated antiglycation activity, with Greek and Sicilian saffron extracts inhibiting AGE formation by ~40%, while Iranian saffron showed 30% inhibition (Ronsisvalle et al., 2023). The ethyl acetate fraction of *Ephedra fragilis* (joint-pine) extract exhibited the strongest antiglycation activity ($IC_{50} = 0.375$ mg/mL), attributed to its high phenolic and flavonoid contents (Guenau et al., 2021). Sesquiterpene lactones obtained from *Inula helenium* (commonly known as elecampane, or horse-heal), particularly alantolactone and isoalantolactone, showed the highest antiglycation activity (97.16% inhibition) (Özcan et al., 2024). Polyphenol-rich agro-residues of pistachio (*Pistachia vera*) green hull and pomegranate (*Punica granatum* L.) peel demonstrated high antiglycation activity, with pomegranate peel extract showing greater inhibition ($IC_{50} = 94$ mg/mL) than pistachio green hull ($IC_{50} = 142$ mg/mL) (Roudbari et al., 2024). *Argania spinosa* (argan) and *Opuntia dillenii* (erect prickly) have also been reported to possess antiglycation activity with active compounds being catechin, kaempferol-O-acetylhexoside, luteolin, and quercetin (Rhizlan et al., 2024). Quercetin, catechin, epicatechin, vanillic acid, and caffeic acid, obtained from *Cocos nucifera* Linn. (coconut) husk fiber extract showed good antiglycation activity ($IC_{50} = 4.50$ μ g/mL) (Oliveira et al., 2021). Similarly, polyphenol extracts of *Arctium lappa* (burdock) and *Symphytum*

officinale (comfrey) showed the strongest antiglycation activity (89.4%) (Chocieł et al., 2024). The methanolic extract of *Pfaffia glomerata* (Brazilian ginseng or canela-velh), with 20-hydroxyecdysone being the major compound, showed below 50% antiglycation activity at a concentration of 10 mg/mL, compared to quercetin control (99%) (Franco et al., 2024).

Anabasis articulata (Forssk) Moq. (Amaranthaceae), also known as ‘Ajrem’ is a shrub spread over halic and xeric regions of Khyber Pakhtunkhwa, Pakistan (Al-Joufi et al., 2022). The phytochemical constituents showed the presence of alkaloids (Boutrif et al., 2024), triterpenoids (Gamal et al., 2022), 30-noroleanane triterpene saponins (El Dine et al., 2019), phenolic compounds (Ben Menni et al., 2024; Kambouche et al., 2019), flavonoids, and carotenoids (Benhammou et al., 2013), sterols (Ben Menni et al., 2022), etc. To date, multiple studies reported that *A. articulata* exhibit antioxidant (Al-Joufi et al., 2022; Benhammou et al., 2013), anti-inflammatory (Ben Menni et al., 2024, 2022; Boutrif et al., 2024), antibacterial (Al-Joufi et al., 2022), antimicrobial (Belyagoubi-Benhammou et al., 2019), larvicidal (Alamri et al., 2024), antidiabetic (Al-Joufi et al., 2022; El Dine et al., 2019), gastroprotective effect (Gamal et al., 2022), anti-arthritic (Abdulhusain et al., 2022), anti-tyrosinase (Jan et al., 2025), anti-acetylcholinesterase (Ben Menni et al., 2022), antiangiogenic (Abdulsahib et al., 2016), and anticancer potentials (Alamri et al., 2024; Monteleone et al., 2024), among others.

Keeping in view the literature mentioning plant extracts and pure compounds that have shown potent thymidine phosphorylase inhibition and antiglycation activities, herein, we attempt to assess the *in vitro* thymidine phosphorylase inhibitory and antiglycation potentials of *A. articulata* HPLC-purified fractions (A-1, D-1, B-1, C-1). In our previous study, we already reported the antibacterial, antioxidant, and antidiabetic potential of *A. articulata* obtained fractions (Al-Joufi et al., 2022). In this study, we further explore the thymidine phosphorylase inhibitory and antiglycation activities of these fractions to evaluate their potential as therapeutic agents for metabolic and age-related disorders.

Material and methods

Plant sample collection

A. articulata (Ajrem) plant stems and leaves were collected from their natural habitat in Mohmand Agency, Pakistan. The collected plant sample (1 kg) was brought to the Herbarium at the Department of Botany, University of Malakand, Khyber Pakhtunkhwa Pakistan, and authenticated by the incharge, who has prior experience in plant taxonomy and identification. The plant material was cleaned, shade-dried, and pulverized into a fine powder.

Extraction

The powdered sample (200 g) was immersed in methanol with continuous vigorous agitation for six days. The mixture was filtered using a Whatman filter paper, and the filtrate was subsequently soaked in methanol for an additional six days. The filtrate was concentrated using a rotary evaporator (Rota vapour R-200 Buchi, Switzerland) under reduced pressure at 40°C. The residual solvent in the semi-solid extract was evaporated by exposing it to open air.

Fractionation

A previously documented procedure utilizing a silica gel column was followed to obtain purified fractions (Haq et al., 2013). The methanolic extract was applied to a silica gel column and eluted with a suitable solvent system. Based on TLC profiling, similar fractions were pooled and designated as pure fractions. The four purified fractions were designated as A1 (5% ethyl acetate solution), B1 (10% ethyl acetate), C1 (30% ethyl acetate), D1 (40% ethyl acetate solution), along with an additional n-hexane fraction. All fractions were stored at 4°C in a refrigerator. The obtained fractions, crude extract, and oil were subsequently subjected to subsequent experimentation.

Thymidine phosphorylase inhibition assay

Thymidine phosphorylase inhibition assay was conducted in triplicate using 96-well plates. Each 200 µL reaction mixture contained 10 µL of the test fraction (0.5 mM; dissolved in DMSO), 150 µL of potassium phosphate buffer (pH 7.0, 50 mM), and 20 µL of TP enzyme (0.058 unit/well). The 96-well plate containing all reagents was subsequently incubated at 30°C for 10 min. Following, 20 µL of 1.5 mM thymidine substrate was added, and the change in optical density was measured at 290 nm for 10 min using a microtiter plate reader (SpectraMax 384, Molecular Devices, San Jose, CA, USA) (Bera et al., 2013). The percentage of inhibition was calculated using *Equation 1*:

$$\% \text{ Inhibition} = \left(1 - \frac{\text{Abs.of sample}}{\text{Abs.of control}}\right) \times 100 \quad (\text{Eq.1})$$

Antiglycation assay

The antiglycation test was carried out as described in the literature, with few modifications (Dos Santos et al., 2022). The assay was performed in 96-well plates, with each well containing 50 µL of bovine serum albumin (BSA) at a concentration of 10 mg/mL, prepared in 100 mM phosphate buffer (pH 7.4), 50 µL of a 14 mM methylglyoxal solution, 20 µL of each fraction (dissolved in DMSO), and 80 µL of phosphate buffer. Sodium azide (3 mM) was incorporated into each well as an antibacterial agent. The plates were incubated at 37 °C for nine days. After incubation, absorbance was measured at 330 nm (excitation) and 420 nm (emission) using a microplate reader (Spectramax M5, Molecular Devices, CA, USA). Rutin served as the reference compound for comparing the activity of test compounds. Percentage inhibition was determined using *Equation 2*:

$$\% \text{ Inhibition} = \left(1 - \frac{\text{Abs.of test sample}}{\text{Abs.of glycated sample}}\right) \times 100 \quad (\text{Eq.2})$$

Statistical analysis

All assays were conducted in triplicate, and the results are presented as mean ± standard error of the mean (SEM). IC₅₀ values for antiglycation activity were calculated by nonlinear regression analysis using GraphPad Prism (version 8.0.2). One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test was applied to determine statistically significant differences among fractions and the standard. A *p*-value less than 0.05 was considered statistically significant.

Results and discussion

Thymidine phosphorylase (TP) inhibition

TP plays a key role in nucleoside metabolism by catalyzing the breaking down of thymidine, a process essential for DNA repair and replication. In various cancers, TP is overexpressed, leading to increased thymidine degradation and the subsequent production of 2-deoxyribose (Warfield and Reigan, 2022). This byproduct contributes to cancer progression by facilitating protein glycation, altering metabolic pathways, modifying the extracellular matrix, and promoting angiogenesis. As a result, targeting TP inhibition has emerged as a potential anticancer strategy (Murmu et al., 2024).

In the present study, inhibition of TP was evaluated for the test compounds, crude extract, oil and standard, as shown in *Table 1*. Purified fractions A-1, D-1, B-1, and C-1 exhibited strong TP inhibition, with % inhibition values ranging from 87.1% to 90.4%. Notably, B-1 and C-1 showed the highest inhibition at 90.4%. A-1 demonstrated the lowest IC₅₀ value (1.9 ± 0.9 mg/mL, $p < 0.01$), followed by B-1 (3.1 ± 0.2 mg/mL, $p < 0.001$) suggesting that both are the most potent inhibitors among the tested compounds. In contrast, C-1 had a much higher IC₅₀ value (80.9 ± 0.2 mg/mL, $p < 0.001$), indicating lower potency despite its high TP inhibition. Fraction D-1 also showed strong TP inhibition with an IC₅₀ value of 6.8 ± 0.7 mg/mL ($p < 0.05$). The crude and oil samples showed moderate inhibition (47.6% and 39.5%, respectively) but were not active enough to determine an IC₅₀ value. The standard inhibitor, 7-deazaxanthine, showed 80.6% inhibition with an IC₅₀ of 15.1 ± 0.1 mg/mL, which was less potent than A-1 but more potent than C-1.

Table 1. Thymidine phosphorylase inhibition activity of tested fractions

Code	% Inhibition	IC ₅₀ ± SEM (mg/mL)
A-1	87.1	$1.9 \pm 0.9^{**}$
D-1	89.2	$6.8 \pm 0.7^*$
B-1	90.4	$3.1 \pm 0.2^{***}$
C-1	90.4	$80.9 \pm 0.2^{***}$
Crude	47.6	Not active
Oil	39.5	Not active
Standard (7-deazaxanthine)	80.6	15.1 ± 0.1

IC₅₀ values are expressed as mean ± SEM (n = 3). Statistical comparisons were made between each sample and the standard (7-deazaxanthine) using unpaired t-tests. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

In the literature, the majority of studies used plant extracts, and pure compounds for the determination of % TP inhibition. Among the three bioactive compounds of *Pistacia integerrima* (zebrawood) namely spinacetin, patuletin, and triterpene pistagremic acid, spinacetin showed the most potent TP inhibition, with an IC₅₀ of 1.9 ± 0.9 μM, followed by patuletin (IC₅₀ of 3.1 ± 0.2 μM), and pistagremic acid (IC₅₀ of 6.8 ± 0.7 μM) (Rauf et al., 2024). Zerumbone, a sesquiterpene found in *Zingiber zerumbet* (bitter ginger) possesses potent TP inhibitory activity (IC₅₀ value of 50.3 ± 0.31 μg/mL) (Albaayit and Mohammed, 2023). Some studies also reported the highest TP inhibition for synthetic compounds, such as benzothiazole-based thiadiazole derivatives (1–15). Notably, compounds 2, 5, 6, and 12 demonstrated excellent inhibition, with IC₅₀ values of

5.70 ± 0.20 µM, 4.50 ± 0.50 µM, 4.60 ± 0.20 µM, and 6.30 ± 0.20 µM, respectively (Khan et al., 2023). Three new acrylic acid derivatives (1–3) isolated from the ethyl acetate fraction of *Achillea millefolium* (common yarrow) demonstrated that compound 3 exhibited the most potent TP inhibitory activity with an IC₅₀ value of 57.81 ± 3.41 µM, followed by compound 2 (IC₅₀ = 89.92 ± 0.37 µM) and compound 1 (IC₅₀ = 158.9 ± 0.97 µM) (Naz et al., 2021). Novel synthesized dihydropyrimidone derivatives (n = 40) act as non-competitive TP inhibitors, and show weak % TP inhibition activity with low IC₅₀ values ranging from 314 to 322.6 µM, respectively (Cui et al., 2023). Bis-thiadiazole bis-Schiff bases were shown to be more potent than the standard drug in inhibiting the thymidine phosphorylase enzyme, with IC₅₀ values ranging from 1.16 to 24.87 µM (Hussain et al., 2023).

Antiglycation assay

Results of the antiglycation activity of the compounds are shown in Table 2. All tested compounds demonstrated significant antiglycation activity, with % inhibition values ranging from 81.6% to 90.3%. The crude extract and oil showed particularly high inhibition with values of 90.3% and 90.1%, respectively. Fraction C-1 exhibited the lowest IC₅₀ value (0.11 ± 0.002 mg/mL, p < 0.01), and an 87.3% inhibition serving as the most potent, followed by oil (0.17 ± 0.004 mg/mL, p < 0.01) and crude extract (1.02 ± 0.013 mg/mL, p < 0.001). Rutin, the standard antiglycation agent, showed the highest % inhibition (96.2%) and the lowest IC₅₀ value (0.02 ± 0.01 mg/mL). However, C-1, oil, and crude extract demonstrated comparable potency, suggesting their potential as natural antiglycation agents. A-1 and B-1 also showed strong activity but with high IC₅₀ values (2.68 ± 0.098 mg/mL and 3.69 ± 0.016 mg/mL, both p < 0.001), respectively.

Table 2. Antiglycation activity of tested fractions

Code	% Inhibition	IC ₅₀ ± SEM (mg/mL)
A-1	87.3	2.68 ± 0.098***
D-1	81.6	3.54 ± 0.028***
B-1	88.0	3.69 ± 0.016***
C-1	89.7	0.11 ± 0.002**
Crude	90.3	1.02 ± 0.013***
Oil	90.1	0.17 ± 0.004**
Standard (Rutin)	96.2	0.02 ± 0.01

IC₅₀ values are expressed as mean ± SEM (n = 3). Statistical comparisons were made between each sample and the standard (Rutin) using unpaired t-tests. *p < 0.05; **p < 0.01; ***p < 0.001

In the literature, the hydroalcoholic extract of *Coffea arabica* (Arabian coffee) and *Coffea canephora* Pierre (robusta coffee) demonstrated the highest antiglycation activity (65.2%) compared to the low-temperature vacuum mediated extract, which showed lower inhibition (47.6%) (Dias et al., 2024). *Solanum aculeatissimum* (Dutch eggplant) aqueous extract showed the highest antiglycation activity (72.8%) in comparison to silver nanoparticles of the extract (67.9%) (Silva et al., 2024). *Punica granatum* L. (pomegranate) peel extract exhibited greater antiglycation activity (IC₅₀ = 94 mg/mL) than *Pistachia vera* (pistachio) green hull extract (IC₅₀ = 142 mg/mL) (Roudbari et al., 2024).

Another study reported that high phenolic and flavonoid contents correlated with the highest antiglycation activity. The ethyl acetate fraction of *Ephedra fragilis* (joint-pine) exhibited the strongest inhibitory activity, with an IC_{50} value of 0.375 mg/mL, followed by water-saturated n-butanol fraction (IC_{50} = 0.595 mg/mL), dichloromethane fraction (IC_{50} = 0.857 mg/mL), crude ethanol extract (IC_{50} = 0.951 mg/mL), and diluted water fraction (IC_{50} = 1.044 mg/mL), while the least activity was shown by hexane fraction with an IC_{50} of 1.212 mg/mL (Guenau et al., 2021). The sesquiterpene lactones, particularly alantolactone and isoalantolactone, from the roots of *Inula helenium* (horse-heal) were extracted exhibited high antiglycation activity (97.1%) compared to the extract obtained using maceration (Özcan et al., 2024). *Crocus sativus* L. (saffron) contains crocin, a glycoside carotenoid that possesses antioxidant and antiglycation activity. Sicilian and Greek saffron extracts exhibited comparable antiglycation activities, each providing approximately 40% inhibition of AGEs formation. In contrast, Iranian saffron was significantly less effective, showing only 30% inhibition ($p < 0.05$) (Ronsisvalle et al., 2023).

The findings of the present study are in good agreement with and greatly add to the body of knowledge on the potential of natural products as TP inhibitors and antiglycation agents. The HPLC-purified fractions from *A. articulata* exhibited significant TP inhibitory activity, with fraction A-1 presenting the lowest IC_{50} value (1.9 ± 0.9 mg/mL), followed by B-1 (3.1 ± 0.2 mg/mL), both demonstrating high inhibition percentages (87.1% and 90.4%, respectively). These values are comparable to previously documented plant-derived TP inhibitors. For instance, spinacetin and patuletin from *Pistacia integerrima* demonstrated IC_{50} values of 1.9 μ M and 3.1 μ M, respectively (Rauf et al., 2024), suggesting a similar order of potency in relative terms, albeit at a lower molar scale. While synthetic compounds such as benzothiazole-based thiadiazole derivatives have exhibited superior potency with IC_{50} values in the low micromolar range (4.5–6.3 μ M) (Khan et al., 2023), the appeal of *A. articulata* lies in its natural origin, and dual bioactivity. Moreover, in contrast to other phytochemicals such as zerumbone (IC_{50} = 50.3 μ g/mL) derived from *Zingiber zerumbet*, A-1 from *A. articulata* exhibits superior TP inhibition (Albaayit and Mohammed, 2023).

The antiglycation assay results also show strong correlation with published data. In the current study, all tested samples from *A. articulata* exhibited significant antiglycation activity, with the crude extract and oil showing inhibition above 90% and IC_{50} values of 1.02 ± 0.013 and 0.17 ± 0.004 mg/mL, respectively. Fraction C-1 was identified as the most effective sample (IC_{50} = 0.11 ± 0.002 mg/mL), exhibiting activity comparable to that of the standard, rutin (IC_{50} = 0.02 ± 0.01 mg/mL). These values surpass earlier documented extracts, including hydroalcoholic *Coffea arabica* (65.2% inhibition) (Dias et al., 2024), *Solanum aculeatissimum* aqueous extract (72.8%) (Silva et al., 2024), and even *Ephedra fragilis* fractions (ethyl acetate fraction IC_{50} = 0.375 mg/mL) (Guenau et al., 2021). The significant antiglycation action may be ascribed to the polyphenolic compounds in *A. articulata*, although further phytochemical characterization is necessary.

The overall findings of this study suggest that the purified fractions of *A. articulata* possess promising dual activity as natural TP inhibitors and antiglycation agents. These in vitro results highlight the potential therapeutic value of *A. articulata* in managing pathological processes associated with cancer and diabetes. Despite this, we acknowledge that the study is limited to in vitro assays and lacks mechanistic insight at the molecular level, including the precise mode of TP inhibition. Furthermore, in vivo validation has not yet been performed. Therefore, further research involving detailed mechanistic

studies, and animal model evaluations are necessary to establish the pharmacological relevance and clinical potential of these findings.

Conclusion

The present study provides preliminary evidence for the thymidine phosphorylase inhibitory and antiglycation potential of HPLC-purified fractions from *Anabasis articulata*. The strong TP inhibition reported in fractions A-1 (87.1%) and B-1 (90.4%) indicates their potential as antiangiogenic agents, which may be advantageous in cancer treatment. Furthermore, B-1 exhibited notable antiglycation activity, indicating its potential involvement in alleviating complications related to diabetes. The findings may be further validated by employing enzyme kinetics studies to determine the manner of TP inhibition, whether competitive, non-competitive, or uncompetitive. Molecular dynamics simulations may further improve the prediction of binding interactions with analogous proteins.

Acknowledgements. The authors wish to thank Princess Nourah bint Abdulrahman University Researchers Supporting Project (number PNURSP2025R33), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, for the financial support.

REFERENCES

- [1] Abdulhusain, Z. H., Mahdi, M. A., Abdulsahib, W. K., Jasim, L. S. (2022): *Anabasis articulata* exerts an anti-arthritic effect on adjuvant-induced arthritis in rats. – *Journal of Advanced Pharmaceutical Technology & Research* 13(4): 276-280.
- [2] Abdulsahib, K., Abdulkareem, A., Ban Jumaa, Q., Hayder, S. (2016): Antiangiogenesis and antioxidant effect of *Anabasis articulata* stems extracts. – *Int J Pharm Sci Rev Res* 41(2): 88-94.
- [3] Alam, A., Khan, M., Halim, S. A., Rehman, N. U., Ayaz, M., Khan, A., Ali, M., Latif, A., Al-Harrasi, A., Ahmad, M. (2024): Synthesis of novel (S)-flurbiprofen-based esters for cancer treatment by targeting thymidine phosphorylase via Biomolecular Approaches. – *Journal of Molecular Structure* 1316: 138970.
- [4] Alamri, A. A., Alanazi, N. A. H., Mashlawi, A. M., Shommo, S. A., Akeel, M. A., Alhejely, A., Sulieman, A. M. E., Salama, S. A. (2024): Chemical Composition of *Anabasis articulata*, and Biological Activity of Greenly Synthesized Zinc Oxide Composite Nanoparticles (Zn-NPs): Antioxidant, Anticancer, and Larvicidal Activities. – *Agronomy* 14(8): 1742.
- [5] Albaayit, S. F. A., Mohammed, M. K. (2023): Antiangiogenic activity and ROS-mediated lung cancer cell line injury of zerumbone. – *Journal of Faculty of Pharmacy of Ankara University* 47(3): 731-738.
- [6] Al-Joufi, F. A., Jan, M., Zahoor, M., Nazir, N., Naz, S., Talha, M., Sadiq, A., Nawaz, A., Khan, F. A. (2022): *Anabasis articulata* (Forssk.) Moq: a good source of phytochemicals with antibacterial, antioxidant, and antidiabetic potential. – *Molecules* 27(11): 3526.
- [7] Belyagoubi-Benhammou, N., Belyagoubi, L., Gismondi, A., Di Marco, G., Canini, A., Atik Bekkara, F. (2019): GC/MS analysis, and antioxidant and antimicrobial activities of alkaloids extracted by polar and apolar solvents from the stems of *Anabasis articulata*. – *Medicinal Chemistry Research* 28: 754-767.
- [8] Ben Menni, D., Belyagoubi-Benhammou, N., Benmahieddine, A., Ben Menni, H., Gismondi, A., Monteleone, V., Di Marco, G., D'Agostino, A., Canini, A., Benamar, H. (2022): Identification of Sterols from *Anabasis articulata* (Forssk.) Moq. (Chenopodiaceae)

- Growing in Algeria and Study of Their Potential Bioactivity. – Waste and Biomass Valorization 13(7): 3283-3295.
- [9] Ben Menni, D., Belyagoubi-Benhammou, N., Abdelli, I., Bekkal Brikci, S., Benmahieddine, A., Ben Menni, H., Boutrif, O., Gismondi, A., Di Marco, G., D'Agostino, A. (2024): Enzyme inhibitory, antioxidant and anti-inflammatory activities of *Anabasis articulata* phenolic-rich extract; in vitro, in vivo, and in silico studies. – Plant Biosystems—An International Journal Dealing with all Aspects of Plant Biology 158(4): 836-851.
 - [10] Benhammou, N., Ghambaza, N., Benabdelkader, S., Atik-Bekkara, F., Panovska, F. K. (2013): Phytochemicals and antioxidant properties of extracts from the root and stems of *Anabasis articulata*. – International Food Research Journal 20(5): 2057.
 - [11] Bera, H., Tan, B. J., Sun, L., Dolzhenko, A. V., Chui, W.-K., Chiu, G. N. C. (2013): A structure–activity relationship study of 1 2 4-triazolo [1 5-a][1 3 5] triazin-5 7-dione and its 5-thioxo analogues on anti-thymidine phosphorylase and associated anti-angiogenic activities. – European Journal of Medicinal Chemistry 67: 325-334.
 - [12] Boutrif, O., Belyagoubi-Benhammou, N., Benmahieddine, A., Abbou, F., Di Marco, G., D'Agostino, A., Canini, A., Gismondi, A. (2024): Antioxidant and in vivo anti-inflammatory properties of alkaloid-rich fractions from the aerial parts of the Algerian *Anabasis articulata*. – Plant Biosystems—An International Journal Dealing with all Aspects of Plant Biology 158(6): 1264-1274.
 - [13] Bronckaers, A., Gago, F., Balzarini, J., Liekens, S. (2009): The dual role of thymidine phosphorylase in cancer development and chemotherapy. – Medicinal Research Reviews 29(6): 903-953.
 - [14] Chocie, P., Foss, K., Jabłońska, M., Ustarbowska, M., Sawicki, T. (2024): The profile and content of polyphenolic compounds and antioxidant and anti-glycation properties of root extracts of selected medicinal herbs. – Plant Foods for Human Nutrition 79(2): 468-473.
 - [15] Cui, T.-M., Altaf, M., Aldarhami, A., Bazaid, A. S., Saeedi, N. H., Alkayyal, A. A., Alshabrm, F. M., Ali, F., Aladhadh, M., Khan, M. Y. (2023): Dihydropyrimidone derivatives as thymidine phosphorylase inhibitors: inhibition kinetics, cytotoxicity, and molecular docking. – Molecules 28(8): 3634.
 - [16] Dias, E. I. C. P. P., Macedo, G. A., Camargo, G. A., Macedo, J. A., Chiocchetti, G. d. M. e. (2024): Effects of extraction processes on recovery, the phenolic profile, and antiglycation activity from green coffee residues (*Coffea arabica* and *Coffea canephora* Pierre). – ACS Sustainable Chemistry & Engineering 12(36): 13464-13474.
 - [17] Dos Santos, F. A., Xavier, J. A., da Silva, F. C., Merlin, J., Goulart, M. O., Rupasinghe, H. (2022): Antidiabetic, antiglycation, and antioxidant activities of ethanolic seed extract of *Passiflora edulis* and piceatannol in vitro. – Molecules 27(13): 4064.
 - [18] El Dine, R. S., Abdallah, H. M., Kandil, Z. A., Zaki, A. A., Khan, S. I., Khan, I. A. (2019): PPAR α and γ activation effects of new nor-triterpenoidal saponins from the aerial parts of *Anabasis articulata*. – Planta medica 85(04): 274-281.
 - [19] Franco, R. R., Franco, R. M., Justino, A. B., Borges, A. L. S., Bittar, V. P., Saito, N., Saraiva, A. L., Júnior, N. N., Otoni, W. C., Espindola, F. S. (2024): Phytochemical composition of aerial parts and roots of *Pfaffia glomerata* (Spreng.) Pedersen and anticholinesterase, antioxidant, and antiglycation activities. – Protoplasma 261(4): 609-624.
 - [20] Gamal, G., Abo-El-Seoud, K. A., Attia, G. (2022): Triterpenoids from the aerial parts of *Anabasis articulata* (Forssk) Moq: gastroprotective effect in vivo with in silico studies, cytotoxic and antimicrobial activities. – Natural Product Research 36(16): 4076-4084.
 - [21] Guenaou, I., Nait Irahah, I., Errami, A., Lahlou, F. A., Hmimid, F., Bourhim, N. (2021): Bioactive compounds from *Ephedra fragilis*: extraction optimization, chemical characterization, antioxidant and antiglycation activities. – Molecules 26(19): 5998.
 - [22] Hammiche, V., Maiza, K. (2006): Traditional medicine in Central Sahara: pharmacopoeia of Tassili N'ajjer. – Journal of Ethnopharmacology 105(3): 358-367.

- [23] Haq, I.-U., Mirza, B., Kondratyuk, T. P., Park, E.-J., Burns, B. E., Marler, L. E., Pezzuto, J. M. (2013): Preliminary evaluation for cancer chemopreventive and cytotoxic potential of naturally growing ethnobotanically selected plants of Pakistan. – *Pharmaceutical Biology* 51(3): 316-328.
- [24] Hussain, R., Rehman, W., Khan, S., Jaber, F., Rahim, F., Shah, M., Khan, Y., Iqbal, S., Naz, H., Khan, I. (2023): Investigation of novel bis-thiadiazole bearing schiff base derivatives as effective inhibitors of thymidine phosphorylase: synthesis, in vitro bioactivity and molecular docking study. – *Saudi Pharmaceutical Journal* 31(11): 101823.
- [25] Jan, M., Shah, A. B., Al-Joufi, F. A., Zahoor, M., Esa, M., ur Rashid, H., Gulfam, N., Shahzad, M. S. (2025): Isolation, characterization, antidiabetic and antityrosinase potentials of compounds isolated from *Anabasis Articulata*. – *Applied Food Research* 100949.
- [26] Javaid, S., Shaikh, M., Fatima, N., Choudhary, M. I. (2019): Natural compounds as angiogenic enzyme thymidine phosphorylase inhibitors: in vitro biochemical inhibition, mechanistic, and in silico modeling studies. – *PloS ONE* 14(11): e0225056.
- [27] Kambouche, N., Hamiani, A., Zitouni, H. (2019): Phenolics compounds and biological activity of leaves of *Anabasis articulata*, an Algerian medicinal plant. – *International Journal of Pharmaceutical Research and Allied Sciences* 8(4-2019): 1-5.
- [28] Khan, Y., Rehman, W., Hussain, R., Khan, S., Maalik, A. (2023): Benzothiazole-based 1 3 4-thiadiazole hybrids derivatives as effective inhibitors of urease and thymidine phosphorylase: synthesis, in vitro and in silico approaches. – *Journal of Molecular Structure* 1291: 135945.
- [29] Lan, H. T. T., Hoan, L. T., Anh, B. T. M., Mai, N. T., Cuong, N. T., Thoa, H. T., Thao, V. M., Dang, N. H., Park, S., Nhiem, N. X. (2024): Flavonol glycosides from the leaves of *Camellia hirsuta* and their α -glucosidase, α -amylase, and advanced glycation end-products inhibitory effects. – *Revista Brasileira de Farmacognosia* 1-7.
- [30] Lee, J. J., Chu, E. (2017): Adherence, dosing, and managing toxicities with trifluridine/tipiracil (TAS-102). – *Clinical colorectal cancer* 16(2): 85-92.
- [31] Majnooni, M. B., Fakhri, S., Ghanadian, S. M., Bahrami, G., Mansouri, K., Iranpanah, A., Farzaei, M. H., Mojarab, M. (2023): Inhibiting angiogenesis by anti-cancer saponins: from phytochemistry to cellular signaling pathways. – *Metabolites* 13(3): 323.
- [32] Monteleone, V., Menni, D. B., Belyagoubi-Benhammou, N., Di Marco, G., Canini, A., Gismondi, A. (2024): *Anabasis articulata* (Forssk.) Moq. food aqueous extract triggers oxidative stress-induced senescence and reduces metastatic power in MDA-MB-231 cells. – *Journal of Functional Foods* 116: 106203.
- [33] Murmu, A., Banjare, P., Matore, B. W., Roy, P. P., Singh, J. (2024): 1 3 4-Oxadiazole: an emerging scaffold to inhibit the thymidine phosphorylase as an anticancer agent. – *Current Medicinal Chemistry* 31(38): 6227-6250.
- [34] Naz, S., Farooq, U., Ma, H., Sarwar, R., Riaz, N. (2021): Three new acrylic acid derivatives from *Achillea mellifolium* as potential thymidine phosphorylase inhibitor: molecular docking and MD simulation studies. – *Journal of Biomolecular Structure and Dynamics* 39(18): 7138-7149.
- [35] Oliveira, M. B., Valentim, I. B., Santos, T. R., Xavier, J. A., Ferro, J. N., Barreto, E. O., Santana, A. E., Melo, L. V., Bottoli, C. B., Goulart, M. O. (2021): Photoprotective and antiglycation activities of non-toxic *Cocos nucifera* Linn. (Arecaceae) husk fiber ethanol extract and its phenol chemical composition. – *Industrial Crops and Products* 162: 113246.
- [36] Özcan, F. Ş., Özcan, N., Dikmen Meral, H., Çetin, Ö., Çelik, M., Trendafilova, A. (2024): Extraction of sesquiterpene lactones from *Inula helenium* roots by high-pressure homogenization and effects on antimicrobial, antioxidant, and antiglycation activities. – *Food and Bioprocess Technology* 17(11): 4071-4082.
- [37] Peeters, M., Cervantes, A., Moreno Vera, S., Taieb, J. (2018): Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. – *Future Oncology* 14(16): 1629-1645.

- [38] Rauf, A., Khan, M., Nizamani, A., Hussain, H., Akram, Z., Al-Awthan, Y. S., Hemeg, H. A., Bahattab, O. S., Ribaud, G. (2024): Multi-target anticancer activity of compounds isolated from galls of *Pistacia chinensis* subsp. *integerrima*: a mechanistic investigation. – *Phytochemistry Letters* 64: 6-12.
- [39] Rhizlan, A., Amine, E., Ouassou, H., Elrherabi, A., Berraouan, A., Legssyer, A., Ziyat, A., Mekhfi, H., Bnouham, M. (2024): In vitro study on antioxidant and antiglycation activities, and molecular docking of Moroccan medicinal plants for diabetes. – *Current Traditional Medicine* 10(7): 201-214.
- [40] Ronsisvalle, S., Panico, A., Santonocito, D., Siciliano, E. A., Sipala, F., Montenegro, L., Puglia, C. (2023): Evaluation of crocin content and in vitro antioxidant and anti-glycation activity of different saffron extracts. – *Plants* 12(20): 3606.
- [41] Roudbari, M., Barzegar, M., Sahari, M. A. (2024): Pistachio green hull and pomegranate peel extracts as two natural antiglycation agents. – *Food Science & Nutrition* 12(5): 3688-3695.
- [42] Seca, A. M., Pinto, D. C. (2018): Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application. – *International Journal of Molecular Sciences* 19(1): 263.
- [43] Silva, R. M. G. d., Do Nascimento Pereira, I., Camargo Zibordi, L., Pereira Rosatto, P. A., Oliveira Granero, F., Malaguti Figueiredo, C. C., Leopoldo Constantino, C. J., da Silva Martin, C., Eloizo Job, A., Nicolau-Junior, N. (2024): Cytotoxic, antioxidant, and antiglycation activities, and tyrosinase inhibition using silver nanoparticles synthesized by leaf extract of *Solanum aculeatissimum* Jacq. – *Journal of Toxicology and Environmental Health, Part A* 87(2): 57-76.
- [44] Teodoro, A. J. (2019): Bioactive compounds of food: their role in the prevention and treatment of diseases. – *Oxidative Medicine and Cellular Longevity* 3765986.
- [45] Warfield, B. M., Reigan, P. (2022): Multifunctional role of thymidine phosphorylase in cancer. – *Trends in Cancer* 8(6): 482-493.